▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #711 by analyst upside · 2026-09-14
KARD
Kardigan, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+128.1%
implied upside to consensus target
Current Price $18.52
Consensus Target $42.25
Bull Target $46.0
Bear Target $37.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
0
Sell
0
52-Week Low $16.25
52-Week High $27.0
YTD Return -15.8%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.09
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $16.25
52-Week High $27.0
Current Price $18.52
Bear Target $37.0
Bull Target $46.0
● Now $18.52 ● Target $42.25
TRADING DATA
Avg Volume 445K
YTD Return -15.8%
Analyst Count 4
Consensus Buy
Upside to Target +128.1%
Last Updated 2026-09-14

ANALYST SUMMARY

Kardigan, Inc. (KARD) is currently trading at $18.52 with a Wall Street consensus price target of $42.25, implying potential upside of 128.1% over the next 12 months. 4 analysts currently cover KARD, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $46.0, while the most cautious has a target of $37.0.

KARD operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 15.8% year-to-date and is currently trading near the lower end of its 52-week range of $16.25 – $27.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GTBIF +120.7%
Green Thumb Industries Inc.
$2B · P/E 13.4x · Buy
MGTX +130.1%
MeiraGTx Holdings plc
$1B · P/E 14.7x · Buy
ADMA +84.2%
ADMA Biologics, Inc.
$2B · P/E 13.2x · Buy
OMER +80.5%
Omeros Corporation
$1B · P/E 11.1x · Hold
INVA +69.4%
Innoviva, Inc.
$1B · P/E 4.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for KARD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan - Reiterated
Overweight → Overweight 2026-08-25 43% win rate (7 calls)
TD Cowen ● Initiated
Buy 2026-07-13 Building track record
Leerink Partners ● Initiated
Outperform 2026-07-13 29% win rate (7 calls)
JP Morgan ● Initiated
Overweight 2026-07-13 43% win rate (7 calls)
Jefferies ● Initiated
Buy 2026-07-13 50% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
12/30
Consensus clarity
20/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →